Record Information |
---|
Version | 2.0 |
---|
Created at | 2006-02-28 10:47:30 UTC |
---|
Updated at | 2024-09-03 04:19:12 UTC |
---|
NP-MRD ID | NP0000293 |
---|
Natural Product DOI | https://doi.org/10.57994/1672 |
---|
Secondary Accession Numbers | None |
---|
Natural Product Identification |
---|
Common Name | 3-Methylxanthine |
---|
Description | 3-Methyl-9H-xanthine is a 3-methylxanthine tautomer where the imidazole proton is located at the 9-position. It has a role as a metabolite. It is a tautomer of a 3-methyl-7H-xanthine. 3-Methylxanthine, also known as 3 MX or purine analog, belongs to the class of organic compounds known as xanthines. These are purine derivatives with a ketone group conjugated at carbons 2 and 6 of the purine moiety. |
---|
Structure | InChI=1S/C6H6N4O2/c1-10-4-3(7-2-8-4)5(11)9-6(10)12/h2H,1H3,(H,7,8)(H,9,11,12) |
---|
Synonyms | Value | Source |
---|
2-oxo-3-Methylhypoxanthine | ChEBI | 3 MX | ChEBI | 3,9-Dihydro-3-methyl-1H-purine-2,6-dione | ChEBI | 3-Methyl-3,7(9)-dihydro-purine-2,6-dione | ChEBI | 3-Methyl-3,9-dihydro-2H,6H-purine-2,6-dione | ChEBI | 3-Methylxanthine, methyl-(13)C-labeled | HMDB | 3-Methylxanthine, monosodium salt | HMDB | 3-Methylxanthine, monopotassium salt | HMDB | 2,6-Dihydroxy-3-methylpurine | HMDB | 3-Methyl xanthine | HMDB | 3-Methyl-3,9-dihydro-purine-2,6-dione | HMDB | Purine analog | HMDB | 3-Methylxanthine | ChEBI |
|
---|
Chemical Formula | C6H6N4O2 |
---|
Average Mass | 166.1374 Da |
---|
Monoisotopic Mass | 166.04908 Da |
---|
IUPAC Name | 3-methyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione |
---|
Traditional Name | 3-methylxanthine |
---|
CAS Registry Number | 1076-22-8 |
---|
SMILES | CN1C2=C(NC=N2)C(=O)NC1=O |
---|
InChI Identifier | InChI=1S/C6H6N4O2/c1-10-4-3(7-2-8-4)5(11)9-6(10)12/h2H,1H3,(H,7,8)(H,9,11,12) |
---|
InChI Key | GMSNIKWWOQHZGF-UHFFFAOYSA-N |
---|
Experimental Spectra |
---|
|
| Spectrum Type | Description | Depositor Email | Depositor Organization | Depositor | Deposition Date | View |
---|
1D NMR | 1H NMR Spectrum (1D, 600 MHz, H2O, simulated) | V.dorna83 | | | 2021-09-06 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, H2O, simulated) | V.dorna83 | | | 2021-09-06 | View Spectrum | HSQC NMR | [1H, 13C] NMR Spectrum (2D, 600 MHz, C2D6OS, experimental) | bgnzk@missouri.edu | MU Metabolomics Center, University of Missouri, Columbia. MO, USA | Dr. Bharat Goel | 2024-01-25 | View Spectrum | HMBC NMR | [1H, 13C] NMR Spectrum (2D, 600 MHz, C2D6OS, experimental) | bgnzk@missouri.edu | MU Metabolomics Center, University of Missouri, Columbia. MO, USA | Dr. Bharat Goel | 2024-01-25 | View Spectrum | COSY NMR | [1H, 1H] NMR Spectrum (2D, 600 MHz, C2D6OS, experimental) | bgnzk@missouri.edu | MU Metabolomics Center, University of Missouri, Columbia. MO, USA | Dr. Bharat Goel | 2024-01-25 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 201 MHz, C2D6OS, experimental) | bgnzk@missouri.edu | MU Metabolomics Center, University of Missouri, Columbia. MO, USA | Dr. Bharat Goel | 2024-01-25 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, C2D6OS, experimental) | bgnzk@missouri.edu | MU Metabolomics Center, University of Missouri, Columbia. MO, USA | Dr. Bharat Goel | 2024-01-25 | View Spectrum | 2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, 5%_DMSO, experimental) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| Predicted Spectra |
---|
|
| Spectrum Type | Description | Depositor ID | Depositor Organization | Depositor | Deposition Date | View |
---|
| Chemical Shift Submissions |
---|
|
| Spectrum Type | Description | Depositor Email | Depositor Organization | Depositor | Deposition Date | View |
---|
1D NMR | 1H NMR Spectrum (1D, 600.133705802, C2D6OS, simulated) | bgnzk@missouri.edu | Sumner Lab, MU Metabolomics Center, University of Missouri, Columbia. MO, USA | Dr. Bharat Goel | 2024-05-14 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, H2O, simulated) | v.dorna83@yahoo.com | Not Available | Not Available | 2021-08-08 | View Spectrum |
| Species |
---|
Species of Origin | |
---|
Species Where Detected | |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as xanthines. These are purine derivatives with a ketone group conjugated at carbons 2 and 6 of the purine moiety. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Imidazopyrimidines |
---|
Sub Class | Purines and purine derivatives |
---|
Direct Parent | Xanthines |
---|
Alternative Parents | |
---|
Substituents | - Xanthine
- Purinone
- Alkaloid or derivatives
- Pyrimidone
- Hydroxypyrimidine
- Pyrimidine
- Heteroaromatic compound
- Imidazole
- Azole
- Azacycle
- Hydrocarbon derivative
- Organopnictogen compound
- Organic oxygen compound
- Organic nitrogen compound
- Organooxygen compound
- Organonitrogen compound
- Organic oxide
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Properties | Property | Value | Reference |
---|
Melting Point | > 300 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 8394 mg/L @ 25 °C (est) | The Good Scents Company Information System | LogP | -0.50 | Gaspari, F., Vigano, G., Orisio, S., Bonati, M., Livio, M., & Remuzzi, G. (1987). Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition. The Journal of clinical investigation, 79(6), 1788-1797. |
|
---|
Predicted Properties | |
---|
General References | - Orlando R, Padrini R, Perazzi M, De Martin S, Piccoli P, Palatini P: Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine. Clin Pharmacol Ther. 2006 May;79(5):489-99. [PubMed:16678550 ]
- Knoppert DC, Spino M, Beck R, Thiessen JJ, MacLeod SM: Cystic fibrosis: enhanced theophylline metabolism may be linked to the disease. Clin Pharmacol Ther. 1988 Sep;44(3):254-64. [PubMed:3046811 ]
- Desiraju RK, Sugita ET, Mayock RL: Determination of theophylline and its metabolites by liquid chromatography. J Chromatogr Sci. 1977 Dec;15(12):563-8. [PubMed:591601 ]
- Tarka SM Jr, Arnaud MJ, Dvorchik BH, Vesell ES: Theobromine kinetics and metabolic disposition. Clin Pharmacol Ther. 1983 Oct;34(4):546-55. [PubMed:6617078 ]
- Tateishi T, Asoh M, Yamaguchi A, Yoda T, Okano YJ, Koitabashi Y, Kobayashi S: Developmental changes in urinary elimination of theophylline and its metabolites in pediatric patients. Pediatr Res. 1999 Jan;45(1):66-70. [PubMed:9890610 ]
- Geraets L, Moonen HJ, Wouters EF, Bast A, Hageman GJ: Caffeine metabolites are inhibitors of the nuclear enzyme poly(ADP-ribose)polymerase-1 at physiological concentrations. Biochem Pharmacol. 2006 Sep 28;72(7):902-10. Epub 2006 Jul 25. [PubMed:16870158 ]
|
---|